A retrospective analysis of microbiology data from general infections was performed. From 105 isolates strains of Staphylococcus spp. 36 (34,28%) were Staphylococcus epidermidis, 33 (31,42%) Staphylococcus aureus, 21 (20%) Staphylococcus haemolyticus, and 15 (14,28%) were Staphylococcus hominis. Results: S. hominis isolates were predominantly resistant to betalactamins (93,33 %) and even Imidazole (60 %). 53,33 % of strains were resistent to aminosides and 33,33 % to Ciprofloxacin. All strains (100%) were sensitive to Vancomycin, but also all were susceptibile to Quinupristin-Dalfopristin. A high percentage of S. hominis were sensitive to Moxifloxacin, Linezolid (93,33 %), and to teicoplanin (86,67%). Discussion: S. hominis is a member of skin normal flora, but all strains of S. hominis were isolated from generalized infection with a high rate of mortality.
1. Kloos, W. & Schleifer, K. (1975). Isolation And Characterization Of Staphylococci From Human Skin. International Journal Of SystematicBacteriology, 25, 62-79;
2. Fitzgibbon, J.E., Nahvi, M.D. & John, J.F. (2010). A Sequence Variant Of Staphylococcus Hominis With A High Prevalence Of Oxacillin And Fluroquinolone Resistance. Research InMicrobiology, 152, 805-810;
3. Palazzo, I.C.V., d’Azevedo, P.A., Secchi, C. & Pignatari, A.C.C. (2008). Staphylococcus Hominis Subsp. Novobiosepticus Strains Causing Nosomical Bloodstream Infection In Brazil. Journal Of Antimicrobial Chemotherapy, 62, 1222-1226;
4. Chavez, F., Alvarez, M.G., Sanz, F., Alba, C. & Joaquin, R.O. (2005). Nosocomical Spread Of Staphylococcus Hominis Subsp. Novobiosepticus Strain Causing Sepsis In A Neonatal Intesive Care Unit. Journal Of ClinicalMicrobiology, 43, 4877-4879;
5. Conde Garcia, R. Seisdedos Elcuaz, E. Jerez Fernandez, R. Ruiz Martin De La Torre, S. Canales Ugarte, T. (2012). General And Risk Management, Patient Safety (Including: Medication Errors, Quality Control) Analysis Of Infections Associated With Central Vascular Catheters Used For Parenteral Nutrition Administration Eur J Hosppharm;19:100 DOI:10.1136/Ejhpharm-2012-000074.41.